Presentation is loading. Please wait.

Presentation is loading. Please wait.

Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire, Isle of Wight and Portsmouth area: National.

Published byぜんま わたぬき Modified over 5 years ago

Similar presentations

Presentation on theme: "Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire, Isle of Wight and Portsmouth area: National."— Presentation transcript:

1 Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire, Isle of Wight and Portsmouth area: National Institute for Health and Care Excellence with atorvastatin off patent compared to three alternativ... Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire, Isle of Wight and Portsmouth area: National Institute for Health and Care Excellence with atorvastatin off patent compared to three alternative models of delivery. Robert Pears et al. Open Heart 2014;1:e000015 ©2014 by British Cardiovascular Society

Download ppt "Evolution over 10 years of costs and benefits of familial hypercholesterolaemia service in Southampton, Hampshire, Isle of Wight and Portsmouth area: National."

Similar presentations

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.

The publication gap in years for the cumulative percent of cited research papers in the ESMO and the UK overall cancer clinical guidelines, with the difference.
MACE rate among CAD severity groups (total 0

MACE rate among CAD severity groups (total 0
Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.

Hazard ratios for the composite primary end-point from sub-group analyses of patents presenting with and without an acute coronary syndrome. Hazard ratios.
Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.

Receiver operating curves (ROC) of the Framingham and QRISK2 risk factor models for predicting 10-year risk of cardiovascular disease with and without.
Flow chart of the used methodology adapted from Moher et al

Flow chart of the used methodology adapted from Moher et al
Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.
Percentage of National Health Service (NHS) expenditure on cardiovascular disease by care setting, England 2012/2013. Percentage of National Health Service.

Percentage of National Health Service (NHS) expenditure on cardiovascular disease by care setting, England 2012/2013. Percentage of National Health Service.
Masashi Maeda et al. Heart Asia 2013;5:7-14

Masashi Maeda et al. Heart Asia 2013;5:7-14
Modelled changes in gastrointestinal endoscopy activity 2013/2014 to 2019/2020.43 2WW, 2-week wait; BCSP, Bowel Cancer Screening Programme; FIT, faecal.

Modelled changes in gastrointestinal endoscopy activity 2013/2014 to 2019/ WW, 2-week wait; BCSP, Bowel Cancer Screening Programme; FIT, faecal.
(A) Image of a stent that was damaged withdrawing it back into a Guideliner V2 after failing to cross the lesion. (A) Image of a stent that was damaged.

(A) Image of a stent that was damaged withdrawing it back into a Guideliner V2 after failing to cross the lesion. (A) Image of a stent that was damaged.
The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.

The procedural journey for our cohort of patients with persistent atrial fibrillation. The procedural journey for our cohort of patients with persistent.
HOMA calculations where glucose is mmol/L and insulin is mU/L

HOMA calculations where glucose is mmol/L and insulin is mU/L
(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.

(A) Kaplan-Meier curve showing AF-free survival after a single procedure for patients grouped according to use of CT integration. (A) Kaplan-Meier curve.
(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.

(A) Safety outcome: risk of major bleeding between triple antiplatelet therapy (TAPT) versus dual antiplatelet therapy (DAPT). (A) Safety outcome: risk.
Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.

Metaregression showing the relationship between mortality and antiplatelet strategy. Metaregression showing the relationship between mortality and antiplatelet.
(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.

(A) 1-year mortality in relation to estimated glomerular filtration rate (eGFR), age (n=47 636) and presence of diabetes mellitus (n=47 624). (A) 1-year.
Comparison of CMR and echocardiography in aortic regurgitation.

Comparison of CMR and echocardiography in aortic regurgitation.
Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.

Correlation of change in H2 concentration (△H2) haemodynamics or laboratory parameters. Correlation of change in H2 concentration (△H2) haemodynamics or.
Changes in smoking behaviour over time.

Changes in smoking behaviour over time.
Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Receiver operating characteristic curves for the association of primary outcome using each clinical risk score and each clinical risk score adjusted for.

Similar presentations

Ads by Google